Highlights

  • Biome Australia (ASX:BIO) shares closed at A$0.27 on 17 August 2026, down 3.57%.
  • FY26 unaudited sales Revenue reached a record A$23.9 million, up 30%.
  • Second-half revenue growth slowed to about 20% from 40% in the first half.
  • Biome generated approximately A$1.6 million of positive Operating Cash Flow in FY26.

Biome Australia (ASX:BIO) enters the final weeks of August with record FY26 sales but a more mixed growth profile. The probiotics company generated unaudited revenue of A$23.9 million, while its flagship Biome Daily product reached the number-one position in Australian community pharmacy by units and dollar sales. However, second-half growth slowed materially compared with the first half, leaving investors focused on whether the moderation was temporary or the beginning of a slower phase.

Why are the shares under pressure?

Biome shares closed at A$0.27 on 17 August 2026, down 3.57% on the day. No company-specific announcement was identified on the date that provides a direct explanation for the decline.

The latest material disclosures were Biome's international markets presentation on 26 July and its June-quarter cash flow report on 28 July. Both highlighted operational progress, including record FY26 revenue and improving cash generation.

The share-price performance instead comes against a broader re-rating of the stock. Despite record revenue, Biome remains near the lower end of its recent trading range, leaving investors to assess whether the Business can translate higher sales into consistent profitability.

What happened?

Biome's FY26 quarterly update reported unaudited sales revenue of A$23.9 million for the year ended 30 June 2026, an increase of 30% from A$18.4 million in FY25.

Fourth-quarter cash receipts reached A$5.9 million, up 61% year on year, while the quarter generated A$708,000 of net operating cash inflow.

The commercial highlight was Biome Daily reaching the number-one probiotic position in Australian community pharmacy by units and dollar sales over the 52 weeks to 27 June 2026, based on IQVIA data.

June also marked the first month in which Activated Probiotics sell-through exceeded 100,000 units.

Biome also entered a binding Manufacturing agreement with Specialty Probiotics Australia in June 2026. The arrangement requires no Capital Investment from Biome, with the first commercial batch targeted for September.

The numbers investors need to know

  • FY26 sales revenue: A$23.9 million, up 30% (unaudited)
  • H1 FY26 revenue: A$12.4 million, up 40%
  • H2 FY26 revenue: approximately A$11.5 million, up about 20%
  • H1 FY26 NPAT: A$1.18 million, up 172%
  • H1 FY26 EBITDA before share-based payments: A$1.47 million
  • H1 FY26 underlying EBITDA after the R&D tax incentive adjustment: A$0.81 million
  • H1 FY26 gross margin: 61.1%
  • FY26 operating cash flow: approximately A$1.6 million inflow
  • Cash at 30 June 2026: A$3.6 million
  • Drawn debt: A$1.9 million of A$5.0 million NAB facilities
  • International revenue: A$1.8 million, up 26%
  • International gross margin: approximately 68%

The change in growth rate is worth monitoring. FY26 revenue increased 30%, but the first-half growth rate of 40% was followed by approximately 20% growth in the second half.

Why this matters

Biome has established a position in Australian pharmacy that provides a more meaningful commercial base than its earlier development-stage profile.

Biome Daily became the leading probiotic product in community pharmacy by both units and dollar sales, while Australian same-store sales were reported to have increased 39% against category growth of approximately 6%.

Gross Margin remained above 61% in H1 FY26, while international operations achieved an approximately 68% gross margin. These figures suggest the company is not relying purely on discounting to generate volume.

The more important financial change is cash generation. FY26 operating cash flow moved to approximately A$1.6 million positive from an A$1.4 million outflow in FY25, giving the business an additional source of funding for expansion.

The bull case

Biome's growth opportunity remains substantial relative to its current revenue base. Management's Vision 27 strategy targets more than A$32 million of FY27 revenue, while the company indicated that the first half of FY27 could become its highest-revenue half on record.

International operations provide another potential source of growth. Revenue across Canada, the United Kingdom, Ireland and New Zealand increased 26% to A$1.8 million, with distribution infrastructure already established across roughly 2,000 points of presence.

The new domestic manufacturing agreement could also improve Supply flexibility and lead times without requiring additional capital expenditure.

The bear case

The major concern is growth deceleration. Second-half revenue of approximately A$11.5 million grew at roughly half the rate recorded during H1 FY26. Management attributed some of the moderation to pharmacy wholesalers reducing inventory at year-end, but the September quarter will need to demonstrate whether that explanation is reflected in renewed sales growth.

Profitability also remains relatively modest. H1 underlying EBITDA after the R&D incentive adjustment was only A$0.81 million, while FY25 net profit was approximately A$215,000.

The Balance Sheet provides limited flexibility, with A$3.6 million of cash against A$1.9 million of drawn Debt as the company continues investing in products and international markets.

What could move the ASX share next?

The Appendix 4E preliminary final report expected at the end of August 2026 should provide the first audited FY26 figures, including gross margin, EBITDA and statutory profit.

The September launch of products manufactured under the new Specialty Probiotics Australia agreement is another important milestone.

Investors will also watch the September-quarter trading performance for evidence that the second-half slowdown was temporary. Management's previously stated FY27 revenue objective and international expansion plans will provide benchmarks against which the next several quarters can be measured.

Outlook

Biome Australia (ASX:BIO) enters FY27 with record sales, positive operating cash flow and a leading pharmacy position for Biome Daily. However, the slowdown from 40% first-half revenue growth to approximately 20% in the second half means the next phase needs to demonstrate renewed acceleration. The 17 August 2026 share price of A$0.27, down 3.57%, reflects that uncertainty. The audited FY26 accounts and September-quarter trading will be important in determining whether the business is beginning to achieve meaningful Operating Leverage or remains primarily a revenue-growth story.